ArticleCanadian respiratory journal
Direct health care costs associated with asthma in British Columbia.
Article in Canadian respiratory journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 67 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase IIa Clinical Trial to Evaluate Pharmacokinetics and Safety of Slow Release DHEA
A Study to Evaluate Efficacy and Safety of Slow Release DHEA
Who cites it
67 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Combination fixed-dose β agonist and steroid inhaler as required for adults or children with mild asthma: a Cochrane systematic review.BMJ evidence-based medicine · 2022Pooled it
- Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma.The Cochrane database of systematic reviews · 2021Pooled it
- Models for estimating and projecting global, regional and national prevalence and disease burden of asthma: a systematic review.Journal of global health · 2020Pooled it
- [Socioeconomic Costs of Asthma in the European Union, United States and Canada: A Systematic Review].Revista espanola de salud publica · 2017Pooled it
- Clinical, economic, and humanistic burden of asthma in Canada: a systematic review.BMC pulmonary medicine · 2013Pooled it
- Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial.Frontiers in immunology · 2024Trial
- Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment.BMC pulmonary medicine · 2017Trial
- Relationship between asthma, obesity and other comorbidities: the Australasian Severe Asthma Registry.Respiratory research · 2026Article
- 'The evidence is out there…': perspectives of healthcare providers on improving asthma and COPD prevention and care within a major health authority region of British Columbia, Canada.BMJ open quality · 2026Article
- Recent Advances and New Therapeutic Goals in the Management of Severe Asthma.Internal medicine (Tokyo, Japan) · 2026Review
- Clinical Remission in Patients with Severe Eosinophilic Asthma - A Single-Arm Observational Study with Benralizumab.Journal of asthma and allergy · 2026Article
- Non-type 2 airway inflammation in severe asthma: from bench to bedside.Frontiers in immunology · 2026Review
- The methyl-CpG binding domain 2 regulates peptidylarginine deiminase 4 expression and promotes neutrophil extracellular trap formation via the Janus kinase 2 signaling pathway in experimental severe asthma.Annals of medicine · 2025Article
- Economic impact of steroid-induced comorbidities in severe asthma: a SHARP CRC simulation.ERJ open research · 2025Article
- Prevalence and Clinical Characteristics of Severe Asthma With Fungal Sensitization in Korea.Allergy, asthma & immunology research · 2025Article
- Clinical Remission Outcome in Chinese Patients With Severe Asthma With an Eosinophilic Phenotype Receiving Mepolizumab: AAllergy, asthma & immunology research · 2025Article
- The effect of a systematic multi-dimensional assessment in severe uncontrolled asthma: a literature review and protocol for an investigator-initiated, open-label, randomized-controlled trial (EXACT@home study).BMC pulmonary medicine · 2025Review
- Article
- Association of Obesity and Severe Asthma in Adults.Journal of clinical medicine · 2024Review
- Impact analysis of infant antibiotic exposure on the burden of asthma: a simulation modeling study.Frontiers in allergy · 2024Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA better understanding of health care costs associated with asthma would enable the estimation of the economic burden of this increasingly common disease.
objectiveTo determine the direct medical costs of asthma-related health care in British Columbia (BC).
methodsAdministrative health care data from the BC Linked Health Database and PharmaNet database from 1996 to 2000 were analyzed for BC residents five to 55 years of age, including the billing information for physician visits, drug dispensations and hospital discharge records. A unit cost was assigned to physician/emergency department visits, and government reimbursement fees for prescribed medications were applied. The case mix method was used to calculate hospitalization costs. All costs were reported in inflation-adjusted 2006 Canadian dollars.
resultsAsthma resulted in $41,858,610 in annual health care-related costs during the study period ($331 per patient-year). The major cost component was medications, which accounted for 63.9% of total costs, followed by physician visits (18.3%) and hospitalization (17.8%). When broader definitions of asthma-related hospitalizations and physician visits were used, total costs increased to $56,114,574 annually ($444 per patient-year). There was a statistically significant decrease in the annual per patient cost of hospitalizations (P<0.01) over the study period. Asthma was poorly controlled in 63.5% of patients, with this group being responsible for 94% of asthma-related resource use.
conclusionThe economic burden of asthma is significant in BC, with the majority of the cost attributed to poor asthma control. Policy makers should investigate the reason for lack of proper asthma control and adjust their policies accordingly to improve asthma management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.